LT3669886T - Kaulų morfogenetiniai baltymai - Google Patents

Kaulų morfogenetiniai baltymai

Info

Publication number
LT3669886T
LT3669886T LTEP19220066.5T LT19220066T LT3669886T LT 3669886 T LT3669886 T LT 3669886T LT 19220066 T LT19220066 T LT 19220066T LT 3669886 T LT3669886 T LT 3669886T
Authority
LT
Lithuania
Prior art keywords
bone morphogenetic
morphogenetic proteins
proteins
bone
morphogenetic
Prior art date
Application number
LTEP19220066.5T
Other languages
English (en)
Inventor
Nicholas W MORRELL
Wei Li
Paul D UPTON
Original Assignee
Cambridge Enterprise, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51453948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3669886(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cambridge Enterprise, Ltd. filed Critical Cambridge Enterprise, Ltd.
Publication of LT3669886T publication Critical patent/LT3669886T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP19220066.5T 2014-07-10 2015-07-09 Kaulų morfogenetiniai baltymai LT3669886T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1412290.7A GB201412290D0 (en) 2014-07-10 2014-07-10 Novel use

Publications (1)

Publication Number Publication Date
LT3669886T true LT3669886T (lt) 2021-06-10

Family

ID=51453948

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP19220066.5T LT3669886T (lt) 2014-07-10 2015-07-09 Kaulų morfogenetiniai baltymai
LTEP15739658.1T LT3166628T (lt) 2014-07-10 2015-07-09 Terapinis kaulų morfogenetinių baltymų panaudojimas

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP15739658.1T LT3166628T (lt) 2014-07-10 2015-07-09 Terapinis kaulų morfogenetinių baltymų panaudojimas

Country Status (21)

Country Link
US (4) US10336800B2 (lt)
EP (3) EP3906936A1 (lt)
JP (1) JP6737770B2 (lt)
KR (2) KR20230049757A (lt)
CN (1) CN106661094B (lt)
AU (1) AU2015287397B2 (lt)
CA (1) CA2954221C (lt)
CY (2) CY1123011T1 (lt)
DK (2) DK3166628T3 (lt)
ES (2) ES2876124T3 (lt)
GB (1) GB201412290D0 (lt)
HR (2) HRP20200418T1 (lt)
HU (2) HUE054512T2 (lt)
LT (2) LT3669886T (lt)
MX (2) MX2017000448A (lt)
PL (2) PL3669886T3 (lt)
PT (2) PT3166628T (lt)
RS (2) RS61961B1 (lt)
RU (1) RU2733318C2 (lt)
SI (2) SI3166628T1 (lt)
WO (1) WO2016005756A1 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
GB201603653D0 (en) * 2016-03-02 2016-04-13 Cambridge Entpr Ltd Combination Therapy
WO2018144968A1 (en) * 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
CA3081152A1 (en) * 2017-11-02 2019-05-09 Bayer Aktiengesellschaft Bispecific antibodies binding alk-1 and bmpr-2
CN107760779B (zh) * 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
CN111939245B (zh) * 2019-05-16 2024-03-01 龚笑海 一种心脏治疗和保护的药物组合物
US20230285506A1 (en) * 2019-12-03 2023-09-14 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
WO2023012318A1 (en) * 2021-08-05 2023-02-09 Actelion Pharmaceuticals Ltd Bmp9 variant polypeptides and uses thereof
CN114317604B (zh) * 2022-03-04 2022-06-17 中国医学科学院阜外医院 一种自发性肺动脉高压模型及构建方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171355A (en) * 1875-12-21 Improvement in driers
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
ATE175441T1 (de) 1991-06-25 1999-01-15 Genetics Inst Bmp-9 zusammensetzungen
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
WO1994026893A1 (en) 1993-05-12 1994-11-24 Genetics Institute, Inc. Bmp-10 compositions
WO1995024474A1 (en) 1994-03-10 1995-09-14 Human Genome Sciences, Inc. Bone morphogenic protein-10
AU2947395A (en) 1995-06-06 1996-12-24 Human Genome Sciences, Inc. Bone morphogenic protein-10
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
WO2006130022A1 (en) 2005-05-30 2006-12-07 Agresearch Limited Modulation of ovulation by agonists and antagonists of bmprii
EP2056852A4 (en) 2006-07-27 2010-01-13 Centocor Ortho Biotech Inc BMP-7 VARIANTS COMPOSITIONS, METHODS AND USES
CN101652387A (zh) 2006-11-02 2010-02-17 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
MX2009012934A (es) 2007-06-01 2009-12-15 Wyeth Corp Metodos y composiciones para modular la actividad de bmp-10.
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
US8999928B2 (en) 2009-04-01 2015-04-07 Indiana University Research And Technology Corporation Methods for treating diseases using a bone morphogenetic protein
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
US9732143B2 (en) * 2011-02-03 2017-08-15 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
CN108178789B (zh) 2011-04-20 2021-11-02 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP INHIBITORS AND METHODS OF USE
GB201412290D0 (en) * 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
EP3496739B1 (en) * 2016-07-15 2021-04-28 Acceleron Pharma Inc. Compositions comprising actriia polypeptides for use in treating pulmonary hypertension
CN107760779B (zh) 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
EP3906936A1 (en) 2021-11-10
MX2020011333A (es) 2020-11-24
SI3166628T1 (sl) 2020-07-31
CN106661094B (zh) 2020-09-08
CA2954221C (en) 2023-02-14
US20190359668A1 (en) 2019-11-28
PL3669886T3 (pl) 2021-09-13
CY1124143T1 (el) 2022-05-27
DK3166628T3 (da) 2020-03-09
US20170121383A1 (en) 2017-05-04
EP3669886B1 (en) 2021-02-24
WO2016005756A1 (en) 2016-01-14
KR102519869B1 (ko) 2023-04-07
ES2770073T5 (es) 2024-03-04
AU2015287397B2 (en) 2020-08-20
CY1123011T1 (el) 2021-10-29
KR20170029576A (ko) 2017-03-15
GB201412290D0 (en) 2014-08-27
ES2876124T3 (es) 2021-11-11
RU2017102381A3 (lt) 2019-02-28
SI3669886T1 (sl) 2021-08-31
MX2017000448A (es) 2017-08-16
HRP20210734T1 (hr) 2021-06-11
PL3166628T5 (pl) 2023-11-27
JP6737770B2 (ja) 2020-08-12
AU2015287397A1 (en) 2017-02-16
EP3166628B1 (en) 2020-01-01
EP3166628A1 (en) 2017-05-17
EP3669886A1 (en) 2020-06-24
RS60181B1 (sr) 2020-06-30
EP3166628B2 (en) 2023-07-26
ES2770073T3 (es) 2020-06-30
CN106661094A (zh) 2017-05-10
DK3669886T3 (da) 2021-05-25
HUE054512T2 (hu) 2021-09-28
LT3166628T (lt) 2020-04-10
JP2017521074A (ja) 2017-08-03
PT3166628T (pt) 2020-04-06
US20170209540A1 (en) 2017-07-27
US10336800B2 (en) 2019-07-02
BR112017000113A2 (pt) 2018-01-02
US20240043485A1 (en) 2024-02-08
HRP20200418T1 (hr) 2020-06-26
KR20230049757A (ko) 2023-04-13
PL3166628T3 (pl) 2020-06-15
PT3669886T (pt) 2021-05-25
RU2733318C2 (ru) 2020-10-01
CA2954221A1 (en) 2016-01-14
HUE048924T2 (hu) 2020-09-28
RS61961B1 (sr) 2021-07-30
US11572396B2 (en) 2023-02-07
RU2017102381A (ru) 2018-08-10

Similar Documents

Publication Publication Date Title
EP3232941C0 (en) SURGICAL SYSTEM
GB201402804D0 (en) Implants
LT3669886T (lt) Kaulų morfogenetiniai baltymai
PL3370652T3 (pl) Wszczep kostny
PL3099791T3 (pl) Białko
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
GB201415344D0 (en) Protein
PL3099793T3 (pl) Białko
GB201418713D0 (en) Bindings Proteins
HRP20181573T1 (hr) Implantat koji sadrži fgf-18
HK1258542A1 (zh) 骨植入物
GB201513033D0 (en) Proteins
GB201517096D0 (en) Surgical aid
ZA201800752B (en) Improved prosthesis for osteosynthesis
GB201513040D0 (en) Bone graft system
EP3389558C0 (de) Banderhaltendes implantat
GB201515744D0 (en) Proteins
GB201503778D0 (en) Proteins
GB201412797D0 (en) Proteins
GB201412649D0 (en) Proteins
GB201412648D0 (en) Proteins
GB201412646D0 (en) Proteins
GB201414371D0 (en) Protein modification
GB201406894D0 (en) Proteins